Brief Ibogaine Bibliography ^^^^^^^^^^^^^^^^^^^^^^^^^^^ 1. Aceto MD, Bowman E, Harris LS, Dependence studies of new compounds in the rhesus monkey, rat and mouse, NIDA Research Monograph, 95:607, 1990. 2. Aceto MD, Bowman E, Harris LS, Dependence studies of new compounds in the rhesus monkey, rat and mouse, NIDA Research Monograph, 119:519-520, 1992. 3. Broderick PA, Phelan FT, Berger SP, Ibogaine alters cocaine induced biogenic amine and psychostimulant dysfunction but not [3H] GBR-12935 binding to the dopamine transporter protein, NIDA Research Monograph, 119:285, 1992. 4. Broderick PA, Phelan FT, Eng F, Wechsler RT, Ibogaine Modulates Cocaine Responses Which Are Altered Due to Environmental Habituation: In Vivo Microvoltammetric and Behavioral Studies, Pharmacology Biochemistry and Behavior, 49(3):711-728, 1994. 5. Cappendijk SLT, Dzoljic MR, Inhibitory effects of ibogaine on cocaine self-administration in rats, European Journal of Pharmacology, 241:261-265, 1993. 6. Cappendijk, SLT, Fekkes D, Dzoljic MR, The inhibitory effects of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine, Behavioural Brain Research, 65:117-119, 1994. 7. Deecher DC, Teitler M, Soderland DM, Bornmann WG, Kuehne MR, Glick SD, Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies, Brain Research, 571:242-247, 1992. 8. Depoortere H, Neocortical Rhythmic Slow Activity during Wakefulness and Paradoxical Sleep in Rats, Neuropsychobiology, 18:160-168, 1987. 9. Dhahir HI, A Comparative Study of the Toxicity of Ibogaine and Serotonin (Doctoral Dissertation, Indiana University) University Microfilms International, 71-25-341, 1971. 10. Dzoljic ED, Kaplan CD, Dzoljic MR, Effects of Ibogaine on Naloxone-Precepitated Withdrawal Syndrome in Chronic Morphine-Dependent Rats, Archive of International Pharmacodynamics, 294:64-70, 1988. 11. Fernandez JW, Bwiti: An Ethnography of the Religious Imagination In Africa, Princeton University Press, 1982. 12. Gallagher CA,Hough LB, Keefner SM, Seyed-Mozaffari A, Archer S and Glick SD, Identification and Quantification of the Indole Alkaloid Ibogaine in Biological Samples by Gas Chromatography-Mass Spectrometry, Biochemical Pharmacology, 49(1):73-79, 1995. 13. Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN, Effects and aftereffects of ibogaine on morphine self-administration in rats, European Journal of Pharmacology, 195:341-345, 1991. 14. Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN, Effects of Ibogaine on Acute Signs of Morphine Withdrawal in Rats: Independence from Tremor, Neuropharmacology, 31(5):497-500, 1992. 15. Glick SD, Gallagher CA, Hough LB, Rossman KL, Maisonneuve IM, Differential effects of ibogaine pretreatment on brain levels of morphine and (+) - amphetamine, Brain Research, 588:173-176, 1992. 16. Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson E, Keller, Jr. RW, Carlson JN, Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorgenic effects and to effects on dopamine release in nucleus accumbens and striatum, Brain Research, 657:14-22, 1994. 17a. Goutarel R, Gollnhofer O, Sillans R, Pharmacodynamics and Therapeutic Applications of Iboga and Ibogaine, Psychedelic Monographs and Essays, vol. 6, 1993. 17b. Goutarel R, Gollnhofer O, Sillans R, L'IBOGA CONTRE LA DEPENDENCE AUX STUPEFIANTS. PHARMACODYNAMIE ET APPLICATIONS PSYCHOTHERAPEAUTIQUES, Psychotropes, 3(3):63-86, 1993. 18. Harsing LG, Sershen H, Lajtha A, Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum, Journal of Neural Transmission, 96:215-225, 1994. 19. Jacobson AE, Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XIII. Drug Tersting Program of the Committee on Problems of Drug Dependence, Inc., NIDA Research Monograph, 95:563, 1990. 20. Kaplan CD, Ketzer E, de Jong J, de Vries M, Reaching a State of Wellness: Multistage Explorations in Social Neuroscience, Social Neuroscience Bulletin, 6(1):6-7, 1993. 21. Keefner SM, Glick SD, Ibogaine Antagonism of Morphine-Induced Hyperactivity: Enhancement by Prior Morphine Exposure and Role of Kappa Opioid Receptors, Society of Neuroscience Abstracts, 20:502.5, 1994. 22. Lotsof HS, U.S. patent 4,499,096; Rapid Method for Interrupting the Narcotic Addiction Syndrome, 1985. 23. Lotsof HS, U.S. patent 4,587,243; Rapid Method for Interrupting the Cocaine and Amphetamine Abuse Syndrome, 1986. 24. Lotsof HS, U.S. patent 4,857,523; Rapid Method for Attenuating The Alcohol Dependency Syndrome, 1989. 25. Lotsof HS, U.S. Patent 5,026,697, Rapid Method for Interrupting or Attenuating The Nicotine/Tobacco Dependency Syndrome., 1991. 26. Lotsof HS, U.S. patent 5,152,994; Rapid Method for Interrupting or Attenuating Poly- drug Dependency Syndromes, 1992. 27. Lotsof HS, Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives (A Preliminary Review), Bull. MAPS, 5(3), 1995. 28. Mash DC, Douyon R, Hearn WL, Sambol NC & Sanchez-Ramos J, A Preliminary Report on the Safety and Pharmacokinetics of Ibogaine, Biological Psychiatry, 1995 In Press. 29. Maisonneuve IM, Keller RW, Glick SD, Interactions between ibogaine, a potential anti- addictive agent and morphine: an in vivo microdialysis study, European Journal of Pharmacology, 199:35-42, 1991. 30. Maisonneuve IM, Glick SD, Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behavior, European Journal of Pharmacology, 212:263- 266, 1992. 31. Maisonneuve IM, Rossman KL, Keller Jr. RW, Glick SD, Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats, Brain Research, 574:69-73, 1992. 32. Maisonneuve IM, Keller Jr. RW, lick, SD, Interactions of ibogaine and D-amphetamine: in vivo microdialysis and motor behavior in rats, Brain Research, 579:87-92, 1992. 33. Molinan HH, Maisonneuve IM, Glick SD, Dose Dependence of Ibogaine Neurotoxicity, Society for Neuroscience Abstracts, 20:504.4, 1994. 34. Naranjo C, Psychotherapeutic Possibilities New Fantasy Enhancing Drugs, Clinical Toxicology, 2(2):209-224, 1969. 35. Naranjo C, The Healing Journey, Pantheon Books, Div. Random House, NY, 174-228, 1973. 36. O'Hearn E, Long DB, Molliver MR, Ibogaine induces glial activation in parasagittal zones of the cerebellum, Neuropharmacology and Neurotoxicology, NeuroReport 4:299- 302, 1993. 37. O'Hearn E, Molliver ME, Degeneration of Purkinje Cells in Parasagittal Zones of the Cerebellar Vermis After Treatment with Ibogaine or Harmaline, Neuroscience, 55(2):303-310, 1993. 38. Pearl SM, Herrick-Davis K, Teitler M, Glick SD, Radioligand-Binding Study of Noribogaine, a Likely Metabolite of Ibogaine, Brain Research, 675, 342-344, 1995. 39. Popik P, Layer RT, Skolnick P, The Putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex, Psychopharmacology, 114:672-674, 1994. 40. Sanchez-Ramos J, Mash DC, Ibogaine Research Update: Phase I Human Study, MAPS, IV(4):11, 1994. 41. Schechter MD, Gordon TL, Comparison of the behavioral effects of ibogaine from three sources: mediation of discrimintive activity, European Journal of Pharmacology 249:70-84, 1993. 42. Schneider JA, McArthur M, Potentiation Action of Ibogaine (Bogadin TM) on Morphine Analgesia, Experientia, XII(8):323-324, 1956. 43. Schneider JA, Sigg EB, Neuropharmacological Studies of Ibogaine, An Indole Alkaloid with Central Stimulant Properties, Annals New York Academy of Sciences, 66:765-776, 1957. 44. Schneider, JA, Rinehart RK, Analysis of the Cardiovascular Action of Ibogaine Hydrochloride, Archive of International Pharmacodynamics, CX(1):92-102, 1957. 45. Sershen H, Hashim A, Harsing L, Lajtha A, Ibogaine Antagonizes Cocaine Induced Locomotor Stimulation in Mice, Life Sciences, 50:1079-1086, 1992. 46. Sershen H, Harsing LG, Hashim A, Lajtha A, Ibogaine Reduces Amphetamine-Induced Locomotor Stimulation C57L/6By Mice, but Stimulates Locomotor Activity in Rats, Life Sciences, 51:10003-1011, 1992. 47. Sershen H, Hashim A, Lajtha A, Ibogaine Reduces Preference for Cocaine Consumption in C57BL/6By Mice, Pharmacology Biochemistry and Behavior. 46:942-948, 1993. 48. Sershen H, Hashim A, Lajtha A, Effects of Ibogaine on Serotonergic and Dopaminergic Interactions in Striatum of Mice and Rats, Neurochemical Research, 19(11):1463- 1465, 1994. 49. Sershen H, Hashim A, Lajtha A, The Effects of Kappa-Opioid and 5-HT3-Induced Changes in Stimulation-Evoked Dopamine Release in Vitro from Striatum of C57BL/By Mice, Brain Research, 36(6):587-591, 1994. 50. Sharpe LG, Jaffe JH, Ibogaine Fails to Reduce Naloxone-Precipitated Withdrawal in the Morphine-Dependent Rat, Neuropharmacology and Neurotoxicology (NeuroReport), 1:17-19, 1990. 51. Sheppard SG, A Preliminary Investigation of Ibogaine: Case Reports and Recommendations for Further Study, Journal of Substance Abuse Treatment, 11(4):379-385, 1994. 52. Sisko B, Interrupting Drug Dependency with Ibogaine: A Summary of Four Case Histories, MAPS 4(2):15-23, 1994. 53. Woods JH, Medzihdsky F, Smith CB, Winger GD, France CP, 1989 Annual Report, Evaluation of New Compounds for Opioid Activity, NIDA Research Monographs, 95:655-656, 1990.